Edition:
United States

Profile: Teva Pharmaceutical Industries Ltd (TEVA.K)

TEVA.K on New York Consolidated

13.84USD
17 Nov 2017
Change (% chg)

$1.05 (+8.21%)
Prev Close
$12.79
Open
$12.73
Day's High
$13.96
Day's Low
$12.71
Volume
40,802,531
Avg. Vol
24,861,432
52-wk High
$39.41
52-wk Low
$10.85

Teva Pharmaceutical Industries Limited, incorporated on February 13, 1944, is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. As of December 31, 2016, the Company had a global portfolio of over 1,800 molecules.

Generic Medicines

The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. It offers a range of basic chemical entities, as well as specialized product families, such as sterile products, hormones, narcotics, high-potency drugs and cytotoxic substances, in both parenteral and solid dosage forms. As of December 31, 2016, the Company produced approximately 300 active pharmaceutical ingredients (APIs) for its own use and for sale to third parties in various therapeutic areas. The Company utilizes a range of production technologies, including chemical synthesis, semi-synthetic fermentation, enzymatic synthesis, plant extract technology and peptides synthesis. As of December 31, 2016, the Company marketed over 500 generic products in over 2,000 dosage strengths and packaging sizes, including oral, injectable and inhaled products. It operates in Venezuela with a product portfolio consisting mainly of branded generic medicines and over-the-counter (OTC) products.

Specialty Medicines

The Company's specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas. The Company's CNS portfolio includes Copaxone for the treatment of relapsing forms of multiple sclerosis, Azilect (rasagiline tablets) for the treatment of the symptoms of Parkinson's disease and Nuvigil (armodafinil) for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders. Its CNS portfolio also includes Actiq (fentanyl oral transmucosal lozenge) for the treatment of pain in opioid-tolerant adult patients with cancer, and Amrix (cyclobenzaprine hydrochloride extended-release capsules) in the United States, for relief of muscle spasm in acute musculoskeletal conditions.

The Company's clinical pipeline of neurology and neuropsychiatry products includes SD-809 (deutetrabenazine), Laquinimod and Pridopidine. The Company's product candidate, SD-809 (deutetrabenazine), is a deuterated form of a small molecule inhibitor of vesicular monoamine 2 transporter (VMAT2) that is designed to regulate the levels of a specific neurotransmitter, dopamine, in the brain. SD-809 is in clinical development for the treatment of tardive dyskinesia. Laquinimod is a once-daily, orally administered immunomodulatory compound. The Company is developing Laquinimod for treatment of relapsing-remitting and progressive forms of multiple sclerosis. Pridopidine is an oral small molecule dopamine stabilizer being developed for the symptomatic treatment of motor disorders, including Huntington disease.

The Company's clinical pipeline of migraine and pain products includes Vantrela ER, TV-46763, TV-46139, TEV-48125 and TV-45070. Vantrela ER is its formulation of hydrocodone, an opioid analgesic, utilizing OraGuard, its abuse deterrence technology platform. TEV-48125 (anti calcitonin gene-related peptide (CGRP)) (fremanezumab) is a fully humanized monoclonal antibody that binds to CGRP. TV-46763 and TV-46139 are pain products with abuse-deterrent properties, developed using its OraGuard technology platform. TV-45070 Topical is a small molecule intended to treat pain locally at its source.

The Company's respiratory portfolio includes ProAir, QVAR, DuoResp Spiromax, Qnasl, Braltus and Cinqair/Cinqaero. The Company's product, ProAir hydrofluoroalkane (HFA) inhalation aerosol with dose counter (albuterol sulfate), is indicated for patients four years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. QVAR (beclomethasone dipropionate HFA) is indicated as a maintenance treatment for asthma as a prophylactic therapy in patients five years of age or older. QVAR is also indicated for asthma patients requiring systemic corticosteroid administration. Duoresp Spiromax (budesonide/formoterol) is a combination of an inhaled corticosteroid (ICS) and a long acting beta-agonist (LABA) bronchodilator. Duoresp Spiromax is indicated for treatment of adults with asthma and chronic obstructive pulmonary disease (COPD) in Europe. Its respiratory portfolio also includes Qnasl Nasal Aerosol.

The Company's delivery systems include breath-actuated inhaler (BAI), Spiromax or RespiClick and Tidal Inhaler. Cinqair/Cinqaero (reslizumab) injection is a humanized interleukin 5 antagonist monoclonal antibody for add-on maintenance treatment of adult patients with asthma and with an eosinophilic phenotype. QVAR BAI US (beclomethasone) is an oral aerosol corticosteroid in development for the treatment of asthma for ages four years and older. Armonair RespiClick is a formulation of long acting ICS using its multi-dose powder inhaler device. Airduo RespiClick is a formulation of ICS/LABA using its multi dose powder inhaler device. TV-44664 is a long acting beta2-agonist and an ICS combined for the treatment of asthma in patients four years of age and older.

The Company's oncology portfolio includes Treanda/Bendeka, Granix and Trisenox in the United States, and Lonquex, Tevagrastim/Ratiograstim and Trisenox outside the United States. Treanda/Bendeka (bendamustine hydrochloride injection) are used for the treatment of patients with chronic lymphocytic leukemia, and patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Filgrastim, which is branded as Tevagrastim in the European Union and Granix in the United States, and Lonquex (lipegfilgrastim), are Granulocyte Colony Stimulating Factor (G-CSF) medicines that stimulate the production of white blood cells, and are primarily used to reduce the risk of infections in oncology patients receiving chemotherapy. Its clinical pipeline of oncology products includes CT-P10 and CT-P6.

The Company's women's health portfolio includes Plan B One-Step OTC/prescription (Rx) (levonorgestrel), along with other products that are marketed in various countries. Plan B One-Step OTC (levonorgestrel) is an oral contraceptive, which consists of a single tablet dose of levonorgestrel for emergency contraception.

The Company competes with Biogen, Novartis AG, Genzyme, GlaxoSmithKline plc, Merck & Co. Inc., Sunovion, AstraZeneca plc, Chiesi, Allergan plc and Bayer AG.

Company Address

Teva Pharmaceutical Industries Ltd

5 Basel St.,
P.O. Box 3190
PETAH TIKVA     49131
P: +9723.9267267
F: +9723.9234050

Company Web Links